Determinants of Exocrine Pancreatic Function as Measured by Fecal Elastase-1 Concentrations (FEC) in Patients with Diabetes mellitus

Nils Ewald, A Raspe, C Kaufmann, R G Bretzel, H U Kloer, P D Hardt, Nils Ewald, A Raspe, C Kaufmann, R G Bretzel, H U Kloer, P D Hardt

Abstract

Objective: Recently it has been shown that there is not only endocrine insufficiency in diabetic patients, but a frequent co-morbidity of both, the endocrine and exocrine pancreas. The present study was performed to further analyse the determinants of exocrine pancreatic function in patients with diabetes mellitus.

Methods: The records of 1992 patients with diabetes mellitus who had been treated in our hospital during a 2-year period were re-evaluated. Defined parameters were documented in standardized data sheets. Records were further checked for the results of imaging procedures of the pancreas. In 307 patients FEC had been performed and documented. Only these patients were included in further evaluation.

Results: FEC was inversely correlated with diabetes duration and HbA1c-levels but not with age. C-peptide levels correlated positively with FEC. BMI and FEC were also significantly correlated. There was no correlation between diabetes therapy and exocrine pancreatic function as there was no correlation with any concomitant medication. The presence of diabetes-associated antibodies was not related to FEC. According to the documented data 38 were classified as type-1 diabetes (12.4%), 167 as type-2 (54.4%), and 88 patients met the diagnostic criteria of type-3 (28.7%). Fourteen patients could not be classified because of lacking information (4.6%).

Conclusions: Exocrine insufficiency might be explained as a complication of diabetes mellitus. However, it is more likely that type-3 diabetes is much more frequent than previously believed. Consequently the evaluation of exocrine function and morphology should be included into the clinical workup of any diabetic patient at least at the time of manifestation.

Figures

Figure 1
Figure 1
Number of patients with exocrine insufficiency as measured by fecal elastase-1 concentrations (FEC).
Figure 2
Figure 2
Fecal elastase-1 concentrations depending on age and gender.
Figure 3
Figure 3
Fecal elastase-1 -concentrations (FEC) and diabetes duration.
Figure 4
Figure 4
Fecal elastase-1-concentrations (FEC) and HbA1c.
Figure 5
Figure 5
Fecal elastase-1-concentrations (FEC) and C-peptide levels.
Figure 6
Figure 6
Fecal elastase-1-concentrations (FEC) and Body Mass Index (BMI).

References

    1. Pollard HM, Miller L, Brewer WA. The external secretion of the pancreas and diabetes mellitus. American Journal of Digestive Diseases. 1943;10:20–23. doi: 10.1007/BF02997405.
    1. Dreilling DA. Studies in pancreatic function. IV. The use of the secretin test in the diagnosis of tumors in and about the pancreas. Gastroenterology. 1951;18:184–196.
    1. Chey WY, Shay H, Shuman CR. External pancreatic secretion in diabetes mellitus. Ann Intern Med. 1963;59:812–821.
    1. Vacca JB, Henke WJ, Knight WA. The exocrine pancreas in diabetes mellitus. Ann Intern Med. 1964;61:242–247.
    1. Frier BM, Saunders JHB, Wormsley KG Bouchier IAD. Exocrine pancreatic function in juvenile-onset diabetes mellitus. Gut. 1976;17:685–691. doi: 10.1136/gut.17.9.685.
    1. Lankisch PG, Manthey G, Otto J, Talaulicar M, Willms B, Creutzfeldt W. Exocrine pancreatic function in insulin-dependent diabetes mellitus. Digestion. 1982;25:210–216.
    1. Scheefers-Borchel U, Scheefers H, Arnold R, Fischer P, Sziegoleit A. Pankreatische Elasatase 1: Parameter für die chronische und akute Pankreatitis. Lab Med. 1992;16:427–432.
    1. Löser C, Möllgaard A, Fölsch UR. Faecal elastase 1: a novel, highly sensitive, and specific tubeless pancreatic function test. Gut. 1996;39:, 580–586.
    1. Hardt PD, Marzeion AM, Schnell-Kretschmer H, Wusten O, Nalop J, Zekorn T. et al.Fecal elastase 1 measurement compared with endoscopic retrograde cholangiopancreatography for the diagnosis of chronic pancreatitis. Pancreas. 2002;25:e6–9. doi: 10.1097/00006676-200207000-00004.
    1. Lankisch PG, Schmidt I, König H, Lehnick D, Knollmann R, Lohr M. et al.Faecal elastase 1: not helpful in diagnosing chronic pancreatitis associated with mild to moderate exocrine pancreatic insufficiancy. Gut. 1998;42:551–554. doi: 10.1136/gut.42.4.551.
    1. Siegmund E, Lohr JM, Schuff-Werner P. The diagnostic validity of non-invasive pancreatic function tests--a metaanalysis. Z Gastroenterol. 2004;42:1117–1128. doi: 10.1055/s-2004-813604.
    1. Molinari I, Souare K, Lamireau T, Fayon M, Lemieux C, Cassaigne A. et al.Fecal chymotrypsin and elastase-1 determination on one single stool collected at random: diagnostic value for exocrine pancreatic status. Clin Biochem. 2004;37:758–763. doi: 10.1016/j.clinbiochem.2004.03.010.
    1. Elphick DA, Kapur K. Comparing the urinary pancreolauryl ratio and faecal elastase-1 as indicators of pancreatic insufficiency in clinical practice. Pancreatology. 2005;5:196–200. doi: 10.1159/000085271.
    1. Hardt PD, Krauss A, Bretz L, Porsch-Oezcueruemez M, Schnell-Kretschmer H, Maeser E. et al.Pancreatic exocrine function in patients with type-1 and type-2 diabetes mellitus. Acta Diabetologia. 2000;37:105–110. doi: 10.1007/s005920070011.
    1. Icks A, Haastert B, Giani G, Rathmann W. Low fecal elastase 1 in type 1 diabetes mellitus. Z Gastroenterol. 2001;39:823–830. doi: 10.1055/s-2001-17867.
    1. Hardt PD, Hauenschild A, Nalop J, Marzeion AM, Jaeger C, Teichmann J. et al.High prevalence of exocrine pancreatic insufficiency in diabetes mellitus. A multicenter study screening fecal elastase 1 concentrations in 1,021 diabetic patients. Pancreatology. 2003;3:395–402. doi: 10.1159/000073655.
    1. Rathmann W, Haastert B, Icks A, Giani G, Hennings S, Mitchell J. et al.Low fecal elastase 1 concentrations in Type 2 diabetes. Scand J Gastroenterol. 2001;36:1056–1061. doi: 10.1080/003655201750422657.
    1. Loehr M, Kloeppel G. Residual insulin positivity and pancreatic atrophy in relation to duration of chronic type 1 (insulin dependent) diabetes mellitus and microangiopathy. Diabetologia. 1987;30:757–762.
    1. Gilbeau J, Poncelet V, Libon E Derue G, Heller FR. The density, contour and thickness of the pancreas in diabetics. Am J Roentgenol. 1992;159:527–531.
    1. Lazarus SS, Volk BW. Pancreas in maturity-onset diabetes. Arch Path (Chicago) 1961;71:44–48.
    1. Gepts W. Pathology of the pancreas in juvenile diabetes. Diabetes. 1965;14:619–633.
    1. Nakanishi K, Kobayashi T, Miyashita H, Okubo M, Sugimoto T, Murase T. et al.Exocrine pancreatic ductograms in insulin-dependent diabetes mellitus. Am J Gastroenterol. 1994;89:762–766.
    1. Hardt PD, Bretz L, Krauss A, Schnell-Kretschmer H, Wüsten O, Nalop J. et al.Pathological pancreatic exocrine function and duct morphology in patients with cholelithiasis. Dig Dis Sci. 2001;46:536–539. doi: 10.1023/A:1005690930325.
    1. Cavalot F, Bonomo K, Perna P, Bacillo E, Salacone P, Gallo M, Mattiello L. et al.Pancreatic elastase-1 in stools, a marker of exocrine pancreas function, correlates with both residual beta-cell secretion and metabolic control in type 1 diabetic subjects. Diabetes Care. 2004;27:2052–2054. doi: 10.2337/diacare.27.8.2052.
    1. The Expert Committee on the diagnosis and classification of Diabetes mellitus. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 1998;21(Suppl 1):5–19.
    1. Alberti KGMM. Diabetes secondary to pancreatopathy: an example of brittle diabetes. In: Tiengo A, Alberti KGMM, DelPrato S, Vranic M, editor. Diabetes secondary to Pancreatopathy. International Congress Series 762. Amsterdam: Excerpta Medica, Amsterdam; 1988. pp. 7–20.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren